Trial Profile
Randomized, Parallel, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of SBI-087 in Seropositive Subjects With Active Rheumatoid Arthritis on a Stable Background of Methotrexate. [Ensayo aleatorizado, de grupos paralelos, en doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de SBI-087 en sujetos seropositivos con artritis reumatoide activa en tratamiento de fondo estable con metotrexato]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs SBI 087 (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Pfizer
- 01 Dec 2016 Primary endpoint (American College of Rheumatology 20% response criteria at 16 weeks) has been met,according to the results published in in The Journal of Rheumatology.
- 01 Dec 2016 Results published in The Journal of Rheumatology (2016).
- 03 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.